Bristol Myers Squibb (NYSE: BMY) has posted better-than-expected second-quarter 2025 results, driven by strong sales of its ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback. At ...

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.

In July 2025, Medtronic Cardiac Rhythm and Heart Failure conducted a study is to demonstrate the efficiency on AT / AF ...

Concomitant atrial fibrillation and end‐stage renal disease is common and associated with an unfavorable prognosis. Although oral anticoagulants have been well established to prevent thromboembolism, ...

A new study published in the medical journal JAMA has raised some concerns for people with atrial fibrillation, a condition ...